Provided by Tiger Trade Technology Pte. Ltd.

Liminatus Pharma LLC

3.75
+0.02000.54%
Post-market: 3.750.00000.00%19:30 EDT
Volume:28.17K
Turnover:105.34K
Market Cap:5.04M
PE:-0.21
High:3.86
Open:3.74
Low:3.65
Close:3.73
52wk High:141.50
52wk Low:3.29
Shares:1.34M
Float Shares:581.43K
Volume Ratio:1.38
T/O Rate:4.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-18.0650
EPS(LYR):-21.4999
ROE:--
ROA:-95.65%
PB:16.76
PE(LYR):-0.17

Loading ...

Liminatus Pharma (LIMN) Stock Is Trending Overnight — Here’s Why it Spiked Over 30% in After-Hours Session (UPDATED)

Benzinga_recent_news
·
Jul 02

Sector Update: Healthcare Stocks Edge Higher Premarket Wednesday

MT Newswires Live
·
Jul 01

Liminatus Pharma amends, restates merger agreement with InnocsAI

TIPRANKS
·
Jul 01

Liminatus Pharma Amends Innocsai Merger Terms, Targets July 2 Close

Reuters
·
Jul 01

Liminatus Pharma - Innocsai Equity Holders to Receive up to 19.99% of Liminatus Common Stock

THOMSON REUTERS
·
Jul 01

Liminatus Pharma Amends Definitive Merger Agreement with Innocsai to Expand Oncology Cell Therapy Pipeline

THOMSON REUTERS
·
Jul 01

Liminatus Pharma - Innocsai Merger Valued at $320 Mln with $0.2 Per Share Issue Price

THOMSON REUTERS
·
Jul 01

Liminatus Pharma Announces Annual Shareholder Meeting

Reuters
·
Jun 30

Liminatus Pharma issues new warrants for 20,688,000 shares in inducement deal

Reuters
·
Jun 03

Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds

THOMSON REUTERS
·
Jun 03

Liminatus Pharma appeals Nasdaq delisting notice after missing $50 million market value rule

Reuters
·
May 28

Liminatus Pharma receives Nasdaq delisting notice

TIPRANKS
·
May 22

Liminatus Pharma appeals Nasdaq delisting notice, trading suspension set May 29

Reuters
·
May 22

Liminatus Pharma Announces Nasdaq Delisting Notification

THOMSON REUTERS
·
May 22

NASD Most Active Issues

Dow Jones
·
May 22

Liminatus Pharma agrees to merge with InnocsAI in $320 million stock deal

Reuters
·
May 21

Liminatus Pharma Inc - Innocsai Members to Receive 20% of Future Net Proceeds From Certain Strategic Deals

THOMSON REUTERS
·
May 21

Liminatus Pharma Announces Proposed Merger With Innocsai to Expand Oncology Cell Therapy Pipeline

THOMSON REUTERS
·
May 21

Top Premarket Gainers

MT Newswires Live
·
May 21

Liminatus Pharma Inc - Enters Merger Agreement With Innocsai Llc on May 17, 2026 - SEC Filing

THOMSON REUTERS
·
May 21